Hua Medicine (HKG:2552) subsidiary Hua Shanghai will terminate its collaboration with Bayer Healthcare for the commercialization of its dorzagliatin tablets for type 2 diabetes, effective Jan. 1, 2025, according to a Friday filing with the Hong Kong Exchange.
Under the agreement, Bayer gained exclusive China commercial rights for HuaTangNing in August 2020.
Hua Medicine may start collaborating with other entities to continue commercializing the diabetes drug, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.